149 related articles for article (PubMed ID: 36286544)
1. Perspectives on the pharmacological management of esophageal cancer: where are we now and where do we need to go?
Rogers JE; Ajani JA
Expert Opin Pharmacother; 2022 Dec; 23(17):1893-1902. PubMed ID: 36286544
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma.
Rogers JE; Yamashita K; Sewastjanow-Silva M; Rosa Vicentini E; Waters R; Ajani JA
Expert Rev Anticancer Ther; 2023 Jun; 23(6):565-571. PubMed ID: 37122102
[TBL] [Abstract][Full Text] [Related]
3. Emerging data on nivolumab for esophageal squamous cell carcinoma.
Hirose T; Yamamoto S; Kato K
Expert Rev Gastroenterol Hepatol; 2021 Aug; 15(8):845-854. PubMed ID: 34251958
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab for the treatment of esophageal cancer.
Mikuni H; Yamamoto S; Kato K
Expert Opin Biol Ther; 2021 Jun; 21(6):697-703. PubMed ID: 33736560
[No Abstract] [Full Text] [Related]
5. Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan.
Harada K; Yamamoto S; Kato K
Expert Opin Biol Ther; 2022 Nov; 22(11):1333-1338. PubMed ID: 36266954
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in treating oesophageal cancer.
Harada K; Rogers JE; Iwatsuki M; Yamashita K; Baba H; Ajani JA
F1000Res; 2020; 9():. PubMed ID: 33042518
[TBL] [Abstract][Full Text] [Related]
7. Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer.
Kadono T; Yamamoto S; Kato K
Jpn J Clin Oncol; 2022 Oct; 52(10):1089-1096. PubMed ID: 36047845
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab for the treatment of esophageal cancer.
Yamamoto S; Kato K
Expert Opin Biol Ther; 2020 Oct; 20(10):1143-1150. PubMed ID: 32620063
[TBL] [Abstract][Full Text] [Related]
9. Esophageal cancer: emerging therapeutics.
Rogers JE; Sewastjanow-Silva M; Waters RE; Ajani JA
Expert Opin Ther Targets; 2022 Feb; 26(2):107-117. PubMed ID: 35119973
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy.
Smyth EC; Gambardella V; Cervantes A; Fleitas T
Ann Oncol; 2021 May; 32(5):590-599. PubMed ID: 33609722
[TBL] [Abstract][Full Text] [Related]
11. Advances in the pharmacotherapeutic management of esophageal squamous cell carcinoma.
Peng C; Cohen DJ
Expert Opin Pharmacother; 2021 Jan; 22(1):93-107. PubMed ID: 33034212
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in esophagogastric cancer.
Ilson DH
Clin Adv Hematol Oncol; 2021 Oct; 19(10):639-647. PubMed ID: 34637430
[TBL] [Abstract][Full Text] [Related]
13. Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical Data.
Kim Y; Yamamoto S; Kato K
Cancer Manag Res; 2023; 15():399-406. PubMed ID: 37197006
[TBL] [Abstract][Full Text] [Related]
14. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation.
Suzuki A; Xiao L; Taketa T; Sudo K; Wadhwa R; Blum MA; Skinner H; Komaki R; Weston B; Lee JH; Bhutani MS; Rice DC; Maru DM; Erasmus J; Swisher SG; Hofstetter WL; Ajani JA
Ann Oncol; 2013 Nov; 24(11):2854-9. PubMed ID: 23994746
[TBL] [Abstract][Full Text] [Related]
15. A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma.
Tang Y; Ou Z; Yao Z; Qiao G
Medicine (Baltimore); 2019 Oct; 98(40):e17164. PubMed ID: 31577707
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Therapies for Esophageal Cancer.
Abdelhakeem A; Blum Murphy M
Thorac Surg Clin; 2022 Nov; 32(4):457-465. PubMed ID: 36266033
[TBL] [Abstract][Full Text] [Related]
17. The clinical efficacy of consolidation chemotherapy for resectable esophageal squamous cell cancer after trimodality therapy.
Sun Y; Cheng S; Lu Y; Zheng X; Ye K; Ge H
J Cancer Res Ther; 2016; 12(1):90-5. PubMed ID: 27072217
[TBL] [Abstract][Full Text] [Related]
18. Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy.
Pelosof L; Saung MT; Donoghue M; Casak S; Mushti S; Cheng J; Jiang X; Liu J; Zhao H; Khazraee M; Goldberg KB; Theoret M; Lemery S; Pazdur R; Fashoyin-Aje L
Oncologist; 2021 Apr; 26(4):318-324. PubMed ID: 33345396
[TBL] [Abstract][Full Text] [Related]
19. The management of localized esophageal squamous cell carcinoma: Western approach.
Zaidi N; Kelly RJ
Chin Clin Oncol; 2017 Oct; 6(5):46. PubMed ID: 29129086
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab for the treatment of advanced esophageal cancer.
Harada K; Yamamoto S; Kato K
Future Oncol; 2022 Jun; 18(18):2311-2319. PubMed ID: 35418242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
